Overview
- ・Target Product: Cell Therapy (CT), Software as Medical Device (SaMD)
- ・Target Timeline: IND by mid 2020’s (CT), by early 2020’s (SaMD)
- ・Target Disease: Malignant, blood disorder, HSCT, Infections, Fertility
- ・Proprietary Technology: Purification/ identification of HSC (initial license from Stanford), joint development with academia, image recognition/ classification, machine learning, federated learning, domain adaptation
- Technology
- Development of Next Generation Medicine Using Stem Cells
- Stem cell utilization tool (highly efficient purification/ex vivo expansion technology).
- Development of evaluation system combining stem cells function analysis and AI･machine learning.
- AI Solution Business Using Machine Learning/Deep Learning
- Early diagnosis and anomaly detection system using clinical image data.
- Treatment optimization (personalized/precision medicine) support system using clinical big data.
- Establishment
- 2016
- Location
- #601 2-24-13 kami-oosaki, Shinagawa-ku, Tokyo 141-0021
- Branch Office
- 6-3-5 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047
- Industry
- Biotech, Medical Device
- Indication
- Cell Therapy, Medical Device (SaMD)
- Funding Round
- Series A
- Raising
- $5mil
-
Product
-
Product
-
Product
Team
-
Masakazu Nakajima Co-founder, CEO
Masakazu (“Masa”) Nakajima is a multi business entrepreneur and investor inside and outside Japan, with profound interests in Japanese art ("sadou", "sumi-e" and beyond)
- ・Kyoto Univ. Mechanical Engineering
- ・New BD in APAC at Itochu Corporation, IT BD at Cyber Agent Inc.
- ・15+ years of alternative investment - Venture Capital & Private Equity (Schroder Ventures, Macquarie Capital
- ・Track record of startup in healthcare space: co-founded, IPO